Major Customers and Segment Data (Tables)

12 Months Ended

Sep. 30, 2011

Major Customers and Segment Data [Abstract]

Consolidated net sales

Year Ended September 30,	2011				2010				2009
Customer A	$	29,632	(19	)%	$	33,821	(24	)%	$	37,876	(26	)%
Customer B	$	18,308	(11	)%	$	18,204	(13	)%	$	19,063	(13	)%

Significant sales information by country for the European Diagnostics and Life Science operating segments

Year Ended September 30,	2011		2010		2009
Italy	$	8,544	$	8,183	$	8,289
France		2,537		2,590		2,939
United Kingdom		2,373		2,646		2,373
Holland		2,142		2,045		1,828
Belgium		1,289		1,291		1,875
Other countries		7,302		7,286		8,566
Total European Diagnostics	$	24,187	$	24,041	$	25,870

Year Ended September 30,	2011		2010		2009
United States	$	15,711	$	13,907	$	13,387
Germany		4,922		3,376		2,816
United Kingdom		4,890		2,575		474
Australia		3,105		1,289		845
France		1,111		1,318		745
Other countries		8,664		4,474		5,167
Total Life Science	$	38,403	$	26,939	$	23,434

Segment information

	U.S.		European
	Diagnostics		Diagnostics		Life Science		Elim (1)			Total
Fiscal Year 2011 -
Net sales -
Third-party	$	97,133	$	24,187	$	38,403	$	—		$	159,723
Inter-segment		10,322		27		756		(11,105	)		—
Operating income (2)		35,191		2,199		2,595		48			40,033
Depreciation and amortization		2,854		116		2,903		—			5,873
Capital expenditures		4,964		77		4,098		—			9,139
Goodwill		1,381		—		21,743		—			23,124
Other intangible assets		1,604		—		9,343		—			10,947
Total assets		73,850		19,390		92,467		(30,214	)		155,493
Fiscal Year 2010 -
Net sales -
Third-party	$	92,020	$	24,041	$	26,939	$	—		$	143,000
Inter-segment		10,285		20		561		(10,866	)		—
Operating income (3)		33,432		3,367		3,615		724			41,138
Depreciation and amortization		2,722		86		1,877		—			4,685
Capital expenditures		1,869		213		1,001		—			3,083
Goodwill		1,381		—		21,921		—			23,302
Other intangible assets		2,283		9		11,035		—			13,327
Total assets		72,030		18,044		90,388		(25,821	)		154,641
Fiscal Year 2009 -
Net sales -
Third-party	$	98,970	$	25,870	$	23,434	$	—		$	148,274
Inter-segment		10,700		6		715		(11,421	)		—
Operating income		39,490		4,459		4,728		102			48,779
Depreciation and amortization		2,680		92		1,588		—			4,360
Capital expenditures		2,082		81		1,480		—			3,643
Goodwill		1,381		—		8,485		—			9,866
Other intangible assets		2,909		24		4,384		—			7,317
Total assets		102,506		18,221		55,592		(20,322	)		155,997

(1)	Eliminations consist of intersegment transactions.
(2)	U.S. Diagnostics and European Diagnostics include $365 and $875, respectively, related to sales and marketing leadership reorganization costs; and Life Science includes $1,057 related to consolidation of the Maine operations into the Tennessee facility.
(3)	Life Science includes $1,240 of Bioline transaction costs.

Pre-tax earnings table

Year Ended September 30,	2011		2010		2009
Segment operating income	$	40,033	$	41,138	$	48,779
Interest income		115		124		456
Other, net		352		138		88
Consolidated earnings before income taxes	$	40,500	$	41,400	$	49,323